The invention relates to a cream, in particular to a chloroiodoxyquine cream. The ointment consists of chloroiodoxyquine, cetostearyl alcohol, polyethylene glycol-6000 and propylene glycol. The invention can more safely and effectively meet the requirements of clinical infant safety medication through prescription comparison and screening.
Description Chloroiodoxyquine creamTechnical Field
The invention relates to a cream, in particular to a chloroiodoxyquine cream.
Background
Chloroiodoxyquine is light yellow to brown yellow loose powder; is similar to special odor and is odorless; is easy to deteriorate when meeting light. Slightly soluble in boiling absolute ethanol, insoluble in water or ethanol; dissolving in hot glacial acetic acid. Can be used for treating suppurative dermatoses, suppurative sore, folliculitis, infectious eczematoid dermatitis, tinea manus, tinea pedis, tinea corporis, tinea cruris, acute eczematoid dermatitis, and dermatoses due to mixed infection of fungi and bacteria.
The chloroiodoxyquin cream can be used for treating suppurative dermatoses, impetigo, folliculitis, infectious eczematoid dermatitis, tinea manus, tinea pedis, tinea corporis, tinea cruris, acute eczematoid dermatitis, and dermatoses due to mixed infection of fungi and bacteria.
The chemical structure of the chloroiodoquinol cream is shown as the following formula:
there are few documents reported to chloroiodoxyquinoline creams.
Chinese patent CN 201610257278.6 describes a pharmaceutical composition of clioquinol and its use in biological medicine. The pharmaceutical composition of the clioquinol provided by the technical scheme contains the clioquinol and a natural product compound with a novel structure, and when the clioquinol and the compound act independently, the pulmonary fibrosis can be inhibited; when chloroiodoxyquine and the compound are combined, the inhibition effect on pulmonary fibrosis is further improved, and the chloroiodoxyquine and the compound can be developed into medicines for inhibiting the fibrosis.
It is known (clinical and experimental study of treatment of candida inter-rash in infants by using chloroiodoxyquine cream, journal of mycology in China, 2 nd month, volume 13, 1 st stage in 2018) that chloroiodoxyquine cream can be used as an external antifungal medicament for infants clinically with the increase of clinical drug-resistant strains.
However, in addition to clinical application, the safety of infant medication is one of important problems to be considered.
Disclosure of Invention
The invention aims to solve the problems and provide the clioquinol emulsifiable paste which can more safely and effectively meet the requirements of clinical infant safety medication through prescription comparison and screening.
In order to achieve the aim, the chloroiodoxyquine emulsifiable paste provided by the invention consists of 2-4% of chloroiodoxyquine, 7.7-8.3% of cetostearyl alcohol, 5.7-6.3% of polyethylene glycol-6000 and the balance of propylene glycol.
The chloroiodoxyquine emulsifiable paste provided by the invention is more preferably prepared by mixing chloroiodoxyquine in the above scheme with 2.7-3.3%.
The preparation method of the clioquinol cream comprises the following steps:
(1) Weighing a part of propylene glycol with the prescription amount, heating to above 75 â, cooling, adding chloroiodoxyquine with the prescription amount, and uniformly adjusting for later use;
(2) Weighing cetostearyl alcohol and polyethylene glycol-6000 according to the prescription amount, heating to above 90 â to form oil phase solution, and then regulating the temperature to above 75 â for later use;
(3) Weighing propylene glycol with the residual prescription amount of 75%, and heating to above 75deg.C for use;
(4) Placing the mixture (3) into a vacuum emulsifying machine, stirring and cooling to 75+/-2 â, adding the mixture (2) into the vacuum emulsifying machine, continuously stirring for 10 minutes to form a matrix, adjusting the matrix to be below 60 â, and preserving the heat for later use;
(5) Adding the component (1) into the component (4), stirring, cooling and stirring until the paste is formed.
The paste can be filled into an aluminum plastic pipe.
Because the prescription of the obtained cream is optimized, the brand new clioquinol cream provided by the invention has better safety and is more suitable for infants.
Detailed Description
The invention will be further described by way of the following examples, which are not intended to limit the scope of the invention in any way. It will be understood by those skilled in the art that equivalent substitutions and corresponding modifications to the technical features of the present invention are included within the scope of the present invention.
Example 1
2% chloroiodoxyquine, 8% cetostearyl alcohol, 6% polyethylene glycol-6000 and the balance propylene glycol are weighed to prepare 10Kg.
(1) Heating the propylene glycol with the prescription amount to above 75 â, cooling, adding chloroiodoxyquine with the prescription amount, and regulating to be uniform;
(2) Weighing cetostearyl alcohol and polyethylene glycol-6000 according to the prescription amount, heating to above 90 â to form oil phase solution, and then regulating the temperature to above 75 â;
(3) Weighing propylene glycol accounting for 75% of the residual prescription amount, and heating to above 75 â;
(4) Placing the mixture (3) into a vacuum emulsifying machine, stirring and cooling to 75+/-2 â, adding the mixture (2) into the vacuum emulsifying machine, continuously stirring for 10 minutes to form a matrix, adjusting the matrix to be below 60 â, and preserving heat;
(5) Adding the component (1) into the component (4), stirring, cooling and stirring until the paste is formed.
Filling the paste into an aluminum plastic pipe.
The product stability is as follows:
example 2
Weighing 4% chloroiodoxyquine, 8.2% cetostearyl alcohol, 6% polyethylene glycol-6000 and the balance propylene glycol to obtain 10Kg.
(1) Heating the propylene glycol with the prescription amount to above 75 â, cooling, adding chloroiodoxyquine with the prescription amount, and regulating to be uniform;
(2) Weighing cetostearyl alcohol and polyethylene glycol-6000 according to the prescription amount, heating to above 90 â to form oil phase solution, and then regulating the temperature to above 75 â;
(3) Weighing propylene glycol accounting for 75% of the residual prescription amount, and heating to above 75 â;
(4) Placing the mixture (3) into a vacuum emulsifying machine, stirring and cooling to 75+/-2 â, adding the mixture (2) into the vacuum emulsifying machine, continuously stirring for 10 minutes to form a matrix, adjusting the matrix to be below 60 â, and preserving heat;
(5) Adding the component (1) into the component (4), stirring, cooling and stirring until the paste is formed
Filling the paste into an aluminum plastic pipe.
The product stability is as follows:
Claims (2)1. a chloroiodoxyquine cream is characterized by comprising 2-4% of chloroiodoxyquine, 7.7-8.3% of cetostearyl alcohol, 5.7-6.3% of polyethylene glycol-6000 and the balance of propylene glycol.
2. A clioquinol cream according to claim 1, characterized in that the clioquinol content is 2.7-3.3%.
CN201910751598.0A 2019-08-15 2019-08-15 Chloroiodoxyquine cream Active CN112386567B (en) Priority Applications (1) Application Number Priority Date Filing Date Title CN201910751598.0A CN112386567B (en) 2019-08-15 2019-08-15 Chloroiodoxyquine cream Applications Claiming Priority (1) Application Number Priority Date Filing Date Title CN201910751598.0A CN112386567B (en) 2019-08-15 2019-08-15 Chloroiodoxyquine cream Publications (2) Family ID=74602692 Family Applications (1) Application Number Title Priority Date Filing Date CN201910751598.0A Active CN112386567B (en) 2019-08-15 2019-08-15 Chloroiodoxyquine cream Country Status (1) Citations (2) * Cited by examiner, â Cited by third party Publication number Priority date Publication date Assignee Title CN102665734A (en) * 2009-09-25 2012-09-12 æ³é©¬ç´¢å°æéå ¬å¸ Surface coatings for skin CN106821987A (en) * 2017-03-16 2017-06-13 åå·å¤§å¦ A kind of liposome and preparation method and application for carrying phenolic hydroxy group insoluble drug Family Cites Families (3) * Cited by examiner, â Cited by third party Publication number Priority date Publication date Assignee Title US20120064135A1 (en) * 2010-09-15 2012-03-15 Norac Pharma Benzoyl Peroxide Composition, Methods for Making Same, and Pharmaceutical or Cosmetic Formulations Comprising Same, and Uses Thereof US9133417B2 (en) * 2012-03-23 2015-09-15 The Procter & Gamble Company Liquid cleaning and disinfecting compositions comprising an assymetrically branched amine oxide WO2015077057A1 (en) * 2013-11-20 2015-05-28 Texas Southern University Methionine aminopeptidase inhibitors for treating infectious diseasesAddress after: No. 221, Huanghai Road, Binhai New Area, Tianjin 300457
Patentee after: Tianjin Pharmaceutical Heping (Tianjin) Pharmaceutical Co.,Ltd.
Country or region after: China
Address before: No. 221, Huanghai Road, Binhai New Area, Tianjin 300457
Patentee before: TIANJIN KINGYORK PHARMACEUTICAL CO.,LTD.
Country or region before: China
2024-03-29 CP03 Change of name, title or addressRetroSearch is an open source project built by @garambo | Open a GitHub Issue
Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo
HTML:
3.2
| Encoding:
UTF-8
| Version:
0.7.4